Profile data is unavailable for this security.
About the company
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
- Revenue in USD (TTM)9.05m
- Net income in USD-33.10m
- Incorporated2015
- Employees36.00
- LocationMereo BioPharma Group PLCOne Cavendish Place, Fourth FloorLONDON W1G0QFUnited KingdomGBR
- Websitehttps://www.mereobiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Terns Pharmaceuticals Inc | 0.00 | -91.06m | 379.01m | 66.00 | -- | 1.60 | -- | -- | -1.26 | -1.26 | 0.00 | 3.66 | 0.00 | -- | -- | 0.00 | -33.23 | -41.34 | -34.55 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
| C4 Therapeutics Inc | 20.04m | -126.07m | 383.25m | 145.00 | -- | 1.48 | -- | 19.13 | -2.37 | -2.37 | 0.3677 | 3.76 | 0.0504 | -- | 2.84 | 138,179.30 | -31.74 | -25.91 | -36.02 | -29.45 | -- | -- | -629.24 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Cibus Inc | 2.32m | -285.67m | 385.87m | 183.00 | -- | 1.18 | -- | 166.32 | -18.29 | -18.29 | 0.1522 | 13.24 | 0.0084 | -- | -- | 12,677.60 | -129.84 | -86.28 | -147.90 | -96.45 | -- | -- | -15,483.49 | -792.07 | -- | -3.17 | 0.0039 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
| Fate Therapeutics Inc | 6.48m | -190.05m | 390.44m | 181.00 | -- | 0.916 | -- | 60.27 | -1.92 | -1.92 | 0.0653 | 3.74 | 0.0108 | -- | 0.9024 | 35,790.05 | -31.67 | -31.82 | -34.36 | -36.05 | -- | -- | -2,933.79 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Biomea Fusion Inc | 0.00 | -127.27m | 400.06m | 110.00 | -- | 2.96 | -- | -- | -3.57 | -3.57 | 0.00 | 3.77 | 0.00 | -- | -- | 0.00 | -90.54 | -- | -107.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| Lenz Therapeutics Inc | 0.00 | -117.37m | 401.40m | 6.00 | -- | 2.02 | -- | -- | -15.88 | -15.88 | 0.00 | 7.77 | 0.00 | -- | -- | 0.00 | -44.51 | -- | -47.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
| Neurogene Inc | 0.00 | -39.03m | 408.75m | 91.00 | -- | 2.37 | -- | -- | -4.58 | -4.58 | 0.00 | 13.28 | 0.00 | -- | -- | 0.00 | -26.57 | -32.70 | -28.41 | -34.73 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| Mereo BioPharma Group plc - ADR | 9.05m | -33.10m | 411.00m | 36.00 | -- | 5.14 | -- | 45.41 | -0.265 | -0.265 | 0.0724 | 0.57 | 0.0756 | -- | 1.06 | 251,399.80 | -27.63 | -- | -38.33 | -- | 73.75 | -- | -365.71 | -- | -- | -- | 0.1389 | -- | -100.00 | -- | -368.73 | -- | -- | -- |
| Contineum Therapeutics Inc | -100.00bn | -100.00bn | 414.40m | 31.00 | -- | -- | -- | -- | -- | -- | -- | 4.66 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| Theravance Biopharma Inc | 61.51m | -44.77m | 415.81m | 99.00 | -- | 2.03 | -- | 6.76 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| ACELYRIN Inc | 0.00 | -240.16m | 417.89m | 130.00 | -- | 0.6477 | -- | -- | -2.59 | -2.59 | 0.00 | 6.52 | 0.00 | -- | -- | 0.00 | -48.23 | -- | -52.78 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Esperion Therapeutics Inc | 229.74m | -86.51m | 426.29m | 240.00 | -- | -- | -- | 1.86 | -1.00 | -1.00 | 1.76 | -1.57 | 0.7353 | 0.7415 | 5.05 | 957,250.00 | -27.69 | -69.45 | -47.42 | -101.81 | 81.85 | -- | -37.65 | -147.44 | 1.78 | -0.6581 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Annexon Inc | 0.00 | -120.74m | 434.34m | 70.00 | -- | 1.62 | -- | -- | -1.46 | -1.46 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -42.15 | -44.06 | -44.99 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| Voyager Therapeutics Inc | 119.04m | -3.04m | 440.59m | 162.00 | -- | 1.29 | 290.24 | 3.70 | -0.1812 | -0.1812 | 2.44 | 6.28 | 0.2954 | -- | 8.27 | 734,839.50 | -0.7554 | 0.6378 | -0.8534 | 0.8203 | -- | -- | -2.56 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 442.22m | 19.00 | -- | 4.48 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
| Adlai Nortye Ltd (ADR) | 5.00m | -104.87m | 443.91m | 127.00 | -- | 5.59 | -- | 88.78 | -7.26 | -7.26 | 0.1931 | 2.15 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -2,097.42 | -- | -- | -1.69 | 0.2843 | -- | -- | -- | -78.38 | -- | -- | -- |
Data as of May 23 2024. Currency figures normalised to Mereo BioPharma Group PLC's reporting currency: US Dollar USD
46.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rubric Capital Management LPas of 15 Apr 2024 | 13.55m | 9.67% |
| Adage Capital Management LPas of 31 Mar 2024 | 9.33m | 6.66% |
| Mangrove Partnersas of 31 Mar 2024 | 8.75m | 6.24% |
| Rock Springs Capital Management LPas of 31 Mar 2024 | 8.14m | 5.81% |
| 683 Capital Management LLCas of 31 Mar 2024 | 5.75m | 4.10% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 5.12m | 3.65% |
| Alkeon Capital Management LLCas of 31 Mar 2024 | 4.24m | 3.02% |
| Suvretta Capital Management LLCas of 31 Mar 2024 | 3.65m | 2.61% |
| Clearline Capital LPas of 31 Mar 2024 | 3.33m | 2.37% |
| Soleus Capital Management LP (Investment Management)as of 31 Mar 2024 | 2.62m | 1.87% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
